Psilocybin-Assisted Therapy for Prolonged Grief
University of Virginia
Summary
The primary purpose of this study is to explore the feasibility of conducting a clinical trial on the effects of psilocybin for individuals with prolonged grief disorder (PGD).
Description
The study aims to investigate whether a single dose of 25 mg psilocybin can reduce the symptoms of grief and trauma associated with Prolonged Grief Disorder (PGD). It is hypothesized that psilocybin will significantly reduce the symptoms of PGD, and that the treatment will facilitate subjective mystical, spiritual, or insightful experiences, which in turn may contribute to the alleviation of grief and trauma symptoms. Neuroimaging will be used to help researchers better understand the relationship between grief and brain functions, comparing pre- and post-dose scans. Participants will undergo…
Eligibility
- Age range
- 18–65 years
- Sex
- All
- Healthy volunteers
- Yes
Inclusion Criteria: * Ages 18 years old up to and including 65 years of age * Negative UDS results for illicit drugs at screening and prior to each drug administration session * Consent to all study procedures * Have an existing diagnosis of Prolonged Grief Disorder. May also be determined to have Complicated Grief Disorder without official diagnosis as determined by PI or designate based on DSM V criteria * Score of greater than 25 on the Inventory of Complicated Grief * Agree to abstain from any psychoactive drugs on the day prior to and the day of the drug administration session * People o…
Interventions
- DrugPsilocybin 25 mg
25 mg psilocybin administered to each participant in single arm, open-label trial
- Diagnostic TestFunctional Magnetic Resonance Imaging (fMRI)
There are two "fMRIs" (functional magnetic resonance imaging) that take place 1-14 days before and 1-14 days after psilocybin administration.
Location
- University of VirginiaCharlottesville, Virginia